Colon and Rectal Cancer Drugs Market Analysis Report, Regional Outlook with Key Players - Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Merck KGaA, Novartis International AG, Sirtex Medical, Sanofi

Coherent Market Insights has announced the addition of the “Colon and Rectal Cancer Drugs Market Size Status and Forecast 2026”, The report classifies the global Colon and Rectal Cancer Drugs Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global Colon and Rectal Cancer Drugs Speaker market, analyzes and researches the Colon and Rectal Cancer Drugs Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Merck KGaA, Novartis International AG, Sirtex Medical, Sanofi S.A. Sorrento Therapeutics, Takeda Pharmaceutical Company

Request sample a copy: https://www.coherentmarketinsights.com/insight/request-sample/2019

Increasing incidence and prevalence of colon and rectal cancer, worldwide and increasing research and development studies for colorectal cancer treatment is expected to drive growth of colon and rectal cancer market in the near future. For instance, according to February 2018 data findings of the American Cancer Society (ACS), colorectal cancer is the third most common cancer diagnosed in both men and women in the U.S.

Moreover, according to the Center for Disease Control and Prevention (CDC), in 2014, around 139,992 people in the U.S. were diagnosed with colorectal cancer, including 73,396 men and 66,596 women. Among which, around 51,651 people in the U.S. died due to colorectal cancer, including 27,134 men and 24,517 women. Furthermore, according to 2012 data findings of the World Health Organization (WHO), colorectal cancer is the third most common cancer in men (746,000 cases, 10.0% of the total) and the second most common in women (614,000 cases, 9.2% of the total) worldwide, in 2012. Furthermore, around 55% of these cases occurred in developed regions.

Increasing number of research and development (R&D) studies by government and private healthcare organizations is also fueling growth of colon and rectal cancer drugs market. For instance, the American Cancer Society (ACS) spend US$ 54 million on colon and rectal cancer research involving 92 research grants, till March 2018.

By Drug Type:

Single Drug
Colon Cancer
Cetuximab
Bevacizumab
Avastin
Capecitabine
Nivolumab
Panitumumab
Oxaliplatin
Others
Rectal Cancer
Avastin
Capecitabine
Erbitux
Cyramza
Irinotecan Hydrochloride
Nivolumab
Others
Combination Drug
Colon Cancer
CAPOX
FOLFOX
FOLFIRI
FOLFIRI-CETUXIMAB
XELIRI
Others
Rectal Cancer
FU-LV
CAPOX
FOLFIRI-BEVACIZUMAB
XELOX
XELIRI
Others

By Distribution Channels:

Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer resulted in slower growth of colon and rectal cancer drugs market. For instance, according to the data published in the National Center for Biotechnology Information (NCBI) in April 2016, there is lack of clinical trials of systemic adjuvant, neoadjuvant, and perioperative chemotherapy for the treatment of colorectal liver metastases (CRLM). These offers lucrative opportunity for the key players to develop new treatment therapy using neoadjuvant agents for resected patients.

Else place an Inquire before Purchase “Colon and Rectal Cancer Drugs Market Size, Status and Forecast 2026 : https://www.coherentmarketinsights.com/insight/talk-to-analyst/2019

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.